Date: 11 March 2021
Author(s): Michael Erman and Maayan Lubell
Pfizer Inc and BioNTech SE said on Thursday that real-world data from Israel suggests their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, meaning it could significantly reduce transmission.
The companies also said the latest analysis of the Israeli data shows the vaccine was 97% effective in preventing symptomatic disease, severe disease and death. That is basically in line with the 95% efficacy Pfizer and BioNTech reported from the vaccine’s late-stage clinical trial in December.
Israel’s Health Ministry, which has been sending data to Pfizer and is working with the healthcare providers giving the vaccine, did not respond to requests for comment.
The analysis also shows real-world evidence of the vaccine’s effectiveness against a highly infectious variant of COVID-199 first discovered in Britain, known as B.1.1.7. More than 80% of the tested specimens when the analysis was conducted were variant B.1.1.7.
There were only a limited number of infection in Israel caused by the so-called South African variant – known as B.1.351 – so they were not able to evaluate effectiveness against this variant.
In terms of population covered, Israel is leading the world in its vaccination programme, thanks in part to an agreement to share data with Pfizer and BioNTech.
As of Wednesday, around 55% of Israel’s 9 million population had been given at least one dose of the Pfizer/BioNTech COVID-19 vaccine, according to Health Ministry data, and 43% have received both doses.
Since the mid-January peak, Israel has seen 71% fewer COVID-19 deaths, 55% fewer cases, 45% fewer new critically ill patients and 40% fewer critically ill patients in hospitals, according to Eran Segal, a data scientist at the Weizmann Institute of Science.
On Wednesday, 2,802 Israelis tested positive -- or 2.9% from nearly 99,000 tests.
According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19 than those who had received the vaccine.
The data, collected from Jan. 17 to March 6, has not yet been peer reviewed.
Israel’s Health Ministry previously found that the Pfizer vaccine developed with Germany’s BioNTech reduces infection, including in asymptomatic cases, by 89.4% and in symptomatic cases by 93.7%. That was in data collected from Jan. 17 to Feb. 6.
Pfizer did not provide further details on its analysis of asymptomatic infections. In a previous unpublished study by the health ministry and Pfizer, Israeli researchers said further study was needed on asymptomatic transmission among people fully vaccinated because they are less likely in Israel to be tested for COVID-19.
Keyword : sterlinghousetrust.com, Sterling House Trust, SHT
Sterling House Trust is a private trust with a difference. It offers its members an exclusive and reliable platform to access unique opportunities and lifestyle services reserved for the select few. With its team of professional managers Sterling House Trust constantly scans the markets and collaborate with reliable global partners to create a portfolio of carefully curated programmes for its members. Members can access these programmes according to their individual needs, interest and financial capacity. Sterling House Trust is headquartered in Auckland, New Zealand, and has operations based in London, UK.
The Sterling House Trust platform was established with the objective of providing its members, secure access to opportunities across a range of global locations, sectors and services.
Our unique Platform was established within the framework of a trust so that the trust would have oversight and governance over the range of services and its quality. Member protection is a core principle and drive in all that we do. Our trustees ensures that the interests and quality of service provided by the Platform are always maintained at the highest standards.
The trust and its trustees provide robust oversight and is constantly on the move to identify and shortlist select opportunities in the international markets. Likewise, we apply the same stringent standards in identifying and selecting providers and professional partners to join our Platform.
The Sterling House Trust Platform utilises our international footfall and relationships to provide our members with access to a range of international opportunities via our global network which covers a broad range of sectors including:
Asset protection, international property ownership and management, alternative and direct ownership, estate planning, banking services, foreign exchange, card services, alternative investment and lifestyle services.
New Zealand Head Office
31/335 Lincoln Road,
14-16 Dowgate Hill,
England EC4R 2SU